Deciphera Pharmaceuticals (NASDAQ:DCPH) issued its quarterly earnings data on Thursday. The company reported ($0.65) earnings per share for the quarter, hitting the consensus estimate of ($0.65), MarketWatch Earnings reports.
DCPH stock remained flat at $$20.00 on Friday. 377,057 shares of the company traded hands, compared to its average volume of 386,467. Deciphera Pharmaceuticals has a 1 year low of $15.15 and a 1 year high of $45.61. The stock has a market cap of $816.87 million, a P/E ratio of -6.69 and a beta of 3.79. The company has a debt-to-equity ratio of 0.05, a quick ratio of 18.44 and a current ratio of 18.44.
Several analysts recently commented on the stock. Leerink Swann assumed coverage on shares of Deciphera Pharmaceuticals in a research report on Monday, September 24th. They issued an “underperform” rating and a $28.00 price target for the company. Canaccord Genuity set a $55.00 price target on shares of Deciphera Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, August 13th. ValuEngine upgraded shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, October 2nd. Raymond James assumed coverage on shares of Deciphera Pharmaceuticals in a research report on Wednesday, August 29th. They issued an “outperform” rating and a $47.00 price target for the company. Finally, Cantor Fitzgerald assumed coverage on shares of Deciphera Pharmaceuticals in a research report on Wednesday, August 22nd. They issued an “overweight” rating and a $53.00 price target for the company. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company. Deciphera Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $45.44.
An institutional investor recently raised its position in Deciphera Pharmaceuticals stock. Bank of New York Mellon Corp boosted its holdings in Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) by 139.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 56,442 shares of the company’s stock after purchasing an additional 32,878 shares during the quarter. Bank of New York Mellon Corp owned about 0.15% of Deciphera Pharmaceuticals worth $2,221,000 at the end of the most recent quarter. 53.52% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This story was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.thelincolnianonline.com/2018/11/10/deciphera-pharmaceuticals-dcph-releases-quarterly-earnings-results-meets-expectations.html.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Read More: Conference Calls and Individual Investors
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.